Strikingly, AAV-Gdf10 treatment in CCl4-induced fibrosis mice decreased serum AST and ALT levels and improved hepatic fibrosis, as evidenced by histological analyses (Fig. S3E-G). This evidence concerns the gene GDF10 and Hepatic fibrosis.